TITLE

Familial occurrence of the May–Hegglin anomaly: is the accompanying renal failure part of a new subentity?

AUTHOR(S)
Demeter, J.; Lelkes, G.; Nemes, L.; Kenéz, A.; Turbucz, P.; de Châtel, R.
PUB. DATE
June 2001
SOURCE
Annals of Hematology;Jun2001, Vol. 80 Issue 6, p368
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We present two cases of the May–Hegglin anomaly discovered in a patient and one of her two sons. The female patient was known to have proteinuria from the age of 14 and was hospitalized in 1980, at the age of 25 years, because of hypertension and proteinuria (1.5 g/day). Thrombocytopenia was found with an abundance of megakaryocytes in the bone marrow. Both steroid treatment and splenectomy failed to ameliorate the thrombocytopenia, thought to be due to idiopathic thrombocytopenic purpura. Progressive renal failure, secondary hyperparathyroidism and uremic osteodystrophy were diagnosed in 1995. In January 1996, when she was hospitalized because of high-grade fever, we saw giant platelets and prominent blue inclusion bodies in almost all granulocytes in the peripheral blood smear. Electron microscopy confirmed the diagnosis of May–Hegglin anomaly in this patient and one of her sons, who at that time showed thrombocytopenia but no renal disease. Three years later, however, at the age of 15, the affected son was found to develop proteinuria. Coexpression of the May–Hegglin anomaly and renal disease, reported previously in a few other patients, may in fact represent a new subentity.
ACCESSION #
15684740

 

Related Articles

  • Rituximab-induced acute thrombocytopenia: a case report and review of the literature. Jun Yi; Seok Kim; Hee Ahn; Su Lee; Myung Chang; Won Kim // Medical Oncology;Mar2009, Vol. 26 Issue 1, p45 

    Abstract  Rituximab is a chimeric monoclonal antibody directed against the phosphoprotein CD20. Because of its efficacy and acceptable toxicity profile, rituximab is now commonly used for the treatment of CD20-positive B-cell malignancies, including B-cell non-Hodgkin’s lymphoma....

  • Monoclonal free light chains can be found in heavy chain diseases. López-Anglada, L.; Puig, N.; Díez-Campelo, M.; Alonso-Ralero, L.; Barrena, S.; Aparicio, M. A.; Gutiérrez, N. C.; García-Sanz, R. // Annals of Clinical Biochemistry;Nov2010, Vol. 47 Issue 6, p570 

    Heavy chain diseases (HCDs) are rare B-cell lymphoproliferative neoplasias characterized by the production of a monoclonal component consisting of a truncated monoclonal Ig heavy chain without the associated light chain. Among them, patients with gamma-HCD are so rare that no more than 150 cases...

  • Drug-induced immune thrombocytopenia. van den Bemt, Patricia M. L. A.; Meyboom, Ronald H. B.; Egberts, Antoine C. G. // Drug Safety;2004, Vol. 27 Issue 15, p1243 

    Thrombocytopenia can have several causes, including the use of certain drugs. The mechanism behind drug-induced thrombocytopenia is either a decrease in platelet production (bone marrow toxicity) or an increased destruction (immune-mediated thrombocytopenia). In addition, pseudothrombocytopenia,...

  • Rosettes in Idiopathic thrombocytopenic purpura - An Unusual Observation. Mathew, Mary; Goel, Garima // Internet Journal of Hematology;2009, Vol. 6 Issue 1, p5 

    Rosettes in the bone marrow can be seen in various malignancies. We report an unusual observation of leukocytes rosetting around megakaryocytes in a child with Immune thrombocytopenic purpura.

  • Bone marrow biopsy morbidity: review of 2003. Bain, B. J. // Journal of Clinical Pathology;Apr2005, Vol. 58 Issue 4, p406 

    Background: Although some hazards are recognised, in general, bone morrow aspiration and trephine biopsy are thought to be safe procedures. Until recently, no attempt hod been made to quantify any attendant risks. For this reason, documentation of adverse events was begun in 2001, under the...

  • Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. Ali, Ridvan; Ozkalemkas, Fahir; Ozkocaman, Vildan; Yakut, Tahsin; Nazlioglu, Hulya Ozturk; Budak, Ferah; Pekgoz, Murat; Korkmaz, Serhat; Karkucak, Mutlu; Ozcelik, Tulay; Tunali, Ahmet // International Journal of Clinical Oncology;Dec2009, Vol. 14 Issue 6, p545 

    Imatinib has shown significant clinical and cytogenetic success in the treatment of chronic myeloid leukemia. Although resistance has been observed in a proportion of patients, sudden blastic crisis is a rare event during imatinib therapy. We describe a 24-year-old male patient with Philadelphia...

  • The Long-term Outlook for Essential Thrombocythemia. Campbell, Peter J.; Green, Anthony R. // Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p157 

    The article discusses the importance of studies on long-term consequences of essential thrombocythemia (ET), a myeloproliferative disorders. Such studies could provide diagnostic work-up and management approaches, comprehensive and complete clinical follow-up, and standardized end point...

  • Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect. Sprangers, B.; Van Wijmeersch, B.; Luyckx, A.; Sagaert, X.; De Somer, L.; Rutgeerts, O.; Lenaerts, C.; Landuyt, W.; Boeckx, N.; Dubois, B.; De Wolf-Peeters, C.; Waer, M.; Billiau, A. D. // Leukemia (08876924);Feb2009, Vol. 23 Issue 2, p340 

    The role of graft-versus-malignancy reactivity in the effects of allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion (DLI) for myelodysplastic syndromes is as yet not well established. Clinical data are limited and animal models are scarce. Here, we report on the...

  • Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome. Pecci, Alessandro; Biino, Ginevra; Fierro, Tiziana; Bozzi, Valeria; Mezzasoma, Annamaria; Noris, Patrizia; Ramenghi, Ugo; Loffredo, Giuseppe; Fabris, Fabrizio; Momi, Stefania; Magrini, Umberto; Pirastu, Mario; Savoia, Anna; Balduini, Carlo; Gresele, Paolo // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: MYH9-related disease (MYH9-RD) is a rare autosomal dominant genetic syndrome characterized by congenital thrombocytopenia associated with the risk of developing progressive nephropathy, sensorineural deafness, and presenile cataract. During the collection of a large case-series of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics